<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04802590</url>
  </required_header>
  <id_info>
    <org_study_id>OASIS-II</org_study_id>
    <nct_id>NCT04802590</nct_id>
  </id_info>
  <brief_title>Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma</brief_title>
  <official_title>A Randomized Phase II Trial Evaluating Ibrutinib Plus CD20 Ab and Venetoclax in Patients With Untreated Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The OASIS II trial is a multicentre, open label, randomized phase II trial. We will compare&#xD;
      the efficacy of Ibrutinib/anti-CD20 Ab versus Ibrutinib/anti-CD20 Ab/Venetoclax given as&#xD;
      fixed duration combinations in newly diagnosed Mantle Cell Lymphoma (MCL) patients (≥ 18&#xD;
      years and &lt; 80 years of age).&#xD;
&#xD;
      Treatment duration of Ibrutinib and Venetoclax will be a maximum of two years. Patients will&#xD;
      be treated with CD20 Ab for 3.5 years.&#xD;
&#xD;
      The primary aim is to assess MRD status at 6 months in both arms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 28, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2031</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minimum residual disease (MRD) rate</measure>
    <time_frame>6 months</time_frame>
    <description>Minimum residual disease rate using droplet digital PCR (ddPCR) in bone marrow (BM) and/or peripheral blood (PB) at the end of induction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRD rate</measure>
    <time_frame>6 months</time_frame>
    <description>MRD response using quantified PCR (qPCR) in PB and BM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD rate</measure>
    <time_frame>12 months</time_frame>
    <description>MRD response using ddPCR in PB and BM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD rate</measure>
    <time_frame>24 months</time_frame>
    <description>MRD response using ddPCR in PB and BM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD rate</measure>
    <time_frame>3 months</time_frame>
    <description>MRD response using ddPCR in PB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD rate</measure>
    <time_frame>18 months</time_frame>
    <description>MRD response using ddPCR in PB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD rate</measure>
    <time_frame>30 months</time_frame>
    <description>MRD response using ddPCR in PB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD rate</measure>
    <time_frame>36 months</time_frame>
    <description>MRD response using ddPCR in PB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD rate</measure>
    <time_frame>42 months</time_frame>
    <description>MRD response using ddPCR in PB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>3 months</time_frame>
    <description>Overall response rate according to Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>6 months</time_frame>
    <description>Overall response rate according to Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>12 months</time_frame>
    <description>Overall response rate according to Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>18 months</time_frame>
    <description>Overall response rate according to Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>24 months</time_frame>
    <description>Overall response rate according to Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>30 months</time_frame>
    <description>Overall response rate according to Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>36 months</time_frame>
    <description>Overall response rate according to Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>42 months</time_frame>
    <description>Overall response rate according to Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate (CRR)</measure>
    <time_frame>3 months</time_frame>
    <description>Complete response rate according to Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRR</measure>
    <time_frame>6 months</time_frame>
    <description>Complete response rate according to Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRR</measure>
    <time_frame>12 months</time_frame>
    <description>Complete response rate according to Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRR</measure>
    <time_frame>18 months</time_frame>
    <description>Complete response rate according to Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRR</measure>
    <time_frame>24 months</time_frame>
    <description>Complete response rate according to Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRR</measure>
    <time_frame>30 months</time_frame>
    <description>Complete response rate according to Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRR</measure>
    <time_frame>36 months</time_frame>
    <description>Complete response rate according to Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRR</measure>
    <time_frame>42 months</time_frame>
    <description>Complete response rate according to Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>5,5 years</time_frame>
    <description>Progression free survival: time from randomization into the study to the first observation of documented clinical disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5,5 years</time_frame>
    <description>Overall survival from the date of randomization to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of MRD negativity</measure>
    <time_frame>5,5 years</time_frame>
    <description>time from the date of attainment the first negative MRD to the date of positive MRD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay from MRD positivity to clinical relapse</measure>
    <time_frame>5,5 years</time_frame>
    <description>time from the date of attainment the first positive MRD based on PB or BM to the first observation of documented disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>5,5 years</time_frame>
    <description>time from attainment of Complete Response (CR) or Partial Response (PR) to the date of first documented disease progression, relapse or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5,5 years</time_frame>
    <description>time from attainment of CR to the date of the first documented disease progression, relapse or death from any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib (+ CD20Ab)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib + Venetoclax (+CD20Ab)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib 560 mg</intervention_name>
    <description>560mg/d continuously from C1D2 to end C24</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax 10 MG Oral Tablet [Venclexta]</intervention_name>
    <description>20mg/d from C2D1 to C2D7</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax 50 MG Oral Tablet [Venclexta]</intervention_name>
    <description>50mg/d from C2D8 to C2D14</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax 100 MG Oral Tablet [Venclexta]</intervention_name>
    <description>100mg/d from C2D15 to C2D21 200mg/d from C2D22 to C2D28 400mg/d from C3D1 to end C24</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is ≥ 18 years and &lt; 80 years of age at the time of signing the informed&#xD;
             consent form (ICF).&#xD;
&#xD;
          2. Patient understood and voluntarily signed and dated an ICF prior to any study-specific&#xD;
             assessments/procedures being conducted.&#xD;
&#xD;
          3. Patient willing and able to adhere to the study visit schedule and other protocol&#xD;
             requirements&#xD;
&#xD;
          4. Women of childbearing potential must have negative results for pregnancy test prior to&#xD;
             study treatment start and agree to abstain from breastfeeding during study&#xD;
             participation and at least 18 months after the last drug administration&#xD;
&#xD;
          5. Men or women of reproductive potential agree to use acceptable method of birth control&#xD;
             during treatment and for eighteen months after the last drug administration.&#xD;
&#xD;
          6. Histologically confirmed (according to the World Health Organization (WHO)&#xD;
             classification) mantle cell lymphoma. The diagnosis has to be confirmed by phenotypic&#xD;
             expression of CD5, CD20 and cyclin D1 or the t(11;14) translocation (by cytogenetics&#xD;
             and/or fluorescence in situ hybridization (FISH) and/or BCL1-IgH PCR)&#xD;
&#xD;
          7. Untreated MCL&#xD;
&#xD;
          8. Adequate renal function as demonstrated by a creatinine clearance &gt; 50 mL/min;&#xD;
             calculated by Cockcroft Gault formula or Modification of Diet in Renal Disease (MDRD)&#xD;
&#xD;
          9. Adequate hepatic function per local laboratory reference range as follow:&#xD;
&#xD;
               -  Aspartate transaminase (AST) and alanine transaminase (ALT) &lt; 3.0 x upper limit&#xD;
                  of normal (ULN)&#xD;
&#xD;
               -  Bilirubin &lt; 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of&#xD;
                  non-hepatic origin)&#xD;
&#xD;
         10. Stage II-IV disease, measurable with at least lymph node &gt; 1.5 cm and requiring&#xD;
             treatment in the opinion of the treating clinician&#xD;
&#xD;
         11. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2.&#xD;
&#xD;
         12. Life expectancy of more than 3 months.&#xD;
&#xD;
         13. For France: patient affiliated to any social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant cardiovascular disease such as uncontrolled or symptomatic&#xD;
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of&#xD;
             screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by&#xD;
             the New York Heart Association Functional Classification.&#xD;
&#xD;
          2. Impaired organ function (other than liver and renal) which will interfere with the&#xD;
             treatment&#xD;
&#xD;
          3. Hemoglobin level &lt; 10g/dL; Neutrophil count &lt;1 G/L; Platelets &lt; 75 G/L (except if&#xD;
             related to lymphoma then platelet must be &gt;50),&#xD;
&#xD;
          4. Major surgery within 28 days before enrollment&#xD;
&#xD;
          5. Known central nervous system lymphoma&#xD;
&#xD;
          6. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.&#xD;
&#xD;
          7. Requires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g.,&#xD;
             phenprocoumon)&#xD;
&#xD;
          8. Requires treatment with strong CYP3A inhibitors&#xD;
&#xD;
          9. Vaccinated with live, attenuated vaccines within 6 months of enrollment (except COVID&#xD;
             vaccine)&#xD;
&#xD;
         10. Known history of human immunodeficiency virus (HIV)&#xD;
&#xD;
         11. Evidence of other clinically significant uncontrolled condition(s) including but not&#xD;
             limited to:&#xD;
&#xD;
               -  Uncontrolled and/or active systemic infection (viral, bacterial or fungal)&#xD;
&#xD;
               -  Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note:&#xD;
                  subjects with serologic evidence of prior vaccination to HBV (i.e. HBs antigen&#xD;
                  negative, anti-HBs antibody + and antiHBc antibody -) and subjects with&#xD;
                  anti-HB-core antibody that are HBV DNA negative may participate&#xD;
&#xD;
         12. Psychiatric illness or condition which could interfere with their ability to&#xD;
             understand the requirements of the study&#xD;
&#xD;
         13. Any life-threatening illness, medical condition, or organ system dysfunction which, in&#xD;
             the investigator' opinion, could compromise the patient safety, interfere with the&#xD;
             absorption or metabolism of treatment (Ibrutinib, CD20 Ab, venetoclax) or put the&#xD;
             study outcomes at undue risk&#xD;
&#xD;
         14. Pregnant, planning to become pregnant, or lactating woman&#xD;
&#xD;
         15. Known hypersensitivity to study treatment (CD20 Ab, Ibrutinib, Venetoclax) or to any&#xD;
             of the excipients&#xD;
&#xD;
         16. Known allergy to xanthine oxidase inhibitors or rasburicase&#xD;
&#xD;
         17. Known glucose-6-phosphate dehydrogenase (G6DP) deficiency&#xD;
&#xD;
         18. Known bleeding disorders&#xD;
&#xD;
         19. Severe prior reactions to monoclonal antibodies or with prior significant toxicity&#xD;
             (other than thrombocytopenia) from Bcl-2 inhibitor&#xD;
&#xD;
         20. History of prior other malignancy with the exception of:&#xD;
&#xD;
               -  curatively treated basal cell carcinoma&#xD;
&#xD;
               -  curatively treated squamous cell carcinoma of the skin or carcinoma in situ of&#xD;
                  the cervix at any time prior to study&#xD;
&#xD;
               -  other curatively treated cancer and patient disease-free for over 5 years&#xD;
&#xD;
         21. Anti-cancer therapies including chemotherapy, radiotherapy or other investigational&#xD;
             therapy, including targeted small molecule agents&#xD;
&#xD;
         22. Biological agents (e.g. monoclonal antibodies) for anti-neoplastic intent: excluded 30&#xD;
             days prior to first dose of venetoclax&#xD;
&#xD;
         23. Person deprived of his/her liberty by a judicial or administrative decision&#xD;
&#xD;
         24. Adult person under legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Le Gouill</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Toby Eyre</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCRI UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Lewis</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCRI UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne FAUGIER</last_name>
    <phone>+33 (0)4 87 91 57 13</phone>
    <email>anne.faugier@lysarc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>A.Z. Sint Jan AV</name>
      <address>
        <city>Bruges</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universite Libre de Bruxelles - Hopital ERASME</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Jolimont</name>
      <address>
        <city>Haine-Saint-Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liege</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universite Catholique de Louvain Mont Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH d'Avignon - Hopital Henri Duffaut</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minioz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut d'Hématologie de Basse Normandie</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD de Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital DUPUYTREN</name>
      <address>
        <city>LIMOGES Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>LYON Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille Cedex</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital St-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital NECKER</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Bordeaux - Hopital Haut-Leveque - Centre Francois Magendie</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Milétrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Annecy Gennevois</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Cornouaille</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de REIMS</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri BECQUEREL</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital René Huguenin</name>
      <address>
        <city>Saint Cloud Cedex</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nancy Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Bretagne Atlantique - Hopital CHUBERT</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave ROUSSY</name>
      <address>
        <city>VILLEJUIF Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

